Filing Flows › Fulgent Genetics (FLGT) › R&D spending
Fulgent Genetics (FLGT) R&D spending by quarter
Fulgent Genetics' R&D spending was $13.6M in Q3 2026 (third quarter 2026), -6% from Q2 2026. Over the last 7 quarters it ranged from $12.4M (Q1 2025) to $14.6M (Q2 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $13.6M | -6% | -2% |
| Q2 2026 | $14.6M | +3% | +8% |
| Q1 2026 | $14.2M | 0% | +14% |
| Q4 2025 | $14.2M | +2% | — |
| Q3 2025 | $13.9M | +3% | — |
| Q2 2025 | $13.5M | +9% | — |
| Q1 2025 | $12.4M | — | — |
Q3 2026 at a glance
Fulgent Genetics, Q3 2026: revenue $90.4M (+8% year over year), operating margin -24.9%, net loss $13.3M, operating cash flow $109M. The chart follows the revenue to costs, profit and cash.
Questions
What is Fulgent Genetics' R&D spending?
Fulgent Genetics' R&D spending was $13.6M in Q3 2026 (third quarter 2026), -6% from Q2 2026.
How has Fulgent Genetics' R&D spending changed?
Over the last 7 quarters it ranged from $12.4M (Q1 2025) to $14.6M (Q2 2026).